The Midwest Bioprocessing Center (MBC) brings important new biobased products to market for human health, nutrition, and personal care. The Company utilizes its proprietary bioprocess platform to produce important new industrial compounds and ingredients from sustainable feedstocks. This bioprocess platform is a combination of enzyme biocatalysis and fermentation systems that specialize in making and combining carbohydrates and lipids – two of the most important classes of molecules of life, with natural products and active ingredients. Lipid and carbohydrate chemistry have notoriously been difficult to address using traditional chemistry. MBC’s bioprocess platform allows the production of high-value lipid and carbohydrate products previously not possible. The company sells its products and services through three distinct brands: iActive™ (cosmetics and personal care), zuCarb™ (Pharmaceutical/Drug Discovery R&D) and MBC Bioprocess Services.
The Midwest Bioprocessing Company (MBC) was formed in 2019 as a spin-off of zuChem, Inc—a pioneer in carbohydrate bioprocess technology for human health and nutrition. MBC acquired zuChem’s zuCarb™ technology platform to produce rare sugars, activated sugars, and other glycochemicals. In late 2020, MBC also acquired the cosmetics technology platform from iActive Naturals to produce novel lipid molecules including the FeruliShield product.
MBC is located in the PeoriaNEXT Innovation Center in Peoria, IL – a biotech incubator adjacent to Bradley University and the USDA National Center for Agricultural Utilization Research (NCAUR). MBC actively collaborates with researchers at NCAUR.
The Midwest Bioprocessing Center Team
David Demirjian, Ph.D.
President & Co-Founder
In addition to managing business efforts at the Midwest Bioprocessing Center, Dr. Demirjian is President and CEO of zuChem, Inc. Prior to founding zuChem, Dr. Demirjian was previously President and Co-Founder of ThermoGen, Inc.—a bioprocessing company that pioneered several chiral biocatalysis technologies for pharmaceutical applications. He is a previous winner of the Research Director’s Association of Chicago “Entrepreneur of the Year Award” (1997) and recipient of the U.S. SBA “Tibbets Award” for successful commercialization of technology developed under the Federal SBIR grant program. Dr. Demirjian became VP of Technology Strategy for MediChem Life Sciences after their acquisition of ThermoGen (May 2000) and oversaw the development of MediChem’s R&D technology platform. Dr. Demirjian helped lead MediChem’s $52MM IPO (Oct. 2000) and was a Director until its acquisition by deCODE Genetics (May 2002). He holds a Ph.D. in Genetics from The University of Chicago and a B.S.A. from the University of Michigan.
Leila Aminova, Ph.D.
Director of Product Development, & Co-Founder
Dr. Leila Aminova specializes in the genetics—molecular biology, enzymology, and protein engineering of genes—important in carbohydrate synthesis and modification. Prior to joining the Midwest Bioprocessing Center, Dr. Aminova worked at zuChem since 2010 developing methods for the large-scale production of activated sugars and oligosaccharides. Dr. Aminova received her MSc in Genetics from Kazan State University (Russia) and her PhD in Microbiology from the Russian Academy of Sciences (Pushchino, Russia, 1998) on the Biochemistry and Physiology of Mutants of Methylotrophic Yeasts. Her postdoctoral work in the Department of Microbiology at the University of Illinois at Urbana-Champaign was related to the effect of bacterial toxins on the cell cycle and cellular pathway on different cell lines. From 2001-2004, Dr. Aminova worked at the Harvard Medical School in the Department of Neuroscience of the Beth Israel Deaconess Medical Center. In 2004, she returned to the University of Illinois at Urbana-Champaign and the study of bacterial toxins on cell differentiation and cellular pathways.
Robert Turner, Ph.D.
Senior Scientist & Co-Founder
Dr. Turner brings almost 20 years of industrial experience in genetic engineering and prokaryotic protein expression to Midwest Bioprocessing Center. He is a skilled molecular/synthetic biologist with broad experience in a wide variety of microorganisms (E. coli, B. subtilis, P. putida, A. baylyi, cyanobacteria, methylotrophs and yeasts). Notable successes have included the economical, scalable manufacture of performance chemicals and biofuel feedstock production, as well as the development of synthetic biology technologies. Dr. Turner has a successful track record of managing teams and executing internal and external projects in synthetic biology, biocatalysis, protein expression, and fermentation technologies. Dr. Turner did postdoctoral research with Professor Paul Schimmel at both MIT (Cambridge, MA) and The Scripps Research Institute (La Jolla, CA). He received his Ph.D. in Biochemistry in 1996 from the University of Illinois, Urbana-Champaign and his B.S. in Biochemistry in 1990 from Illinois Benedictine College in Lisle, IL.
Bryant Pero, Ph.D.
Dr. Pero specializes in organic synthesis, specifically with carbohydrate and glycomimetic chemistry. During his graduate studies, Dr. Pero investigated therapeutic alternatives to antibiotics by synthesizing carbohydrate mimetics for two pathogenic lectins – FimH in uropathogenic E. coli and Fap2 in F. nucleatum. Dr. Pero brings an in-depth understanding of infection initiation and the role that carbohydrates play in the interaction between the host and pathogen. He received a Ph.D. in Organic Chemistry from the University of Connecticut in 2022 and a B.S. in Biochemistry from Saginaw Valley State University in 2017.
Elena is the Marketing Manager of Midwest Bioprocessing Center. She has an MA in PR & Advertising and a Marketing MBA from DePaul University. She graduated with her BA from Columbia College Chicago in Creative Writing.